Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SI | P14410 | 1/20 | 0.46 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15945454 | 1.00 | MGAM (0.46) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL2607864 | 0.95 | — | — | |
| SCHEMBL3037432 | 0.92 | MGAM (0.48) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL11956800 | 0.82 | TSHR (0.46) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL12534515 | 0.82 | TSHR (0.46) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL7550561 | 0.82 | ALDH1A1 (0.43) | GAATSHRALDH1A1HSD17B10LMNA | |
| SCHEMBL129132 | 0.81 | MGAM (0.52) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL16743578 | 0.80 | TSHR (0.43) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL9889314 | 0.80 | ALDH1A1 (0.62) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL10001051 | 0.80 | MGAM (0.67) | MGAMGAASIMGAM2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455641-B2 | Method for producing 4,4′-(propane-1,2-diyl)-dipiperazine-2,6-dione | CYATHUS EXQUIRERE PHARMAFORSCHUNGS GMBH (AT) | 2013-06-04 | — | — | US | disclosed |
| US-20100152447-A1 | Novel Method for Producing 4,4-(1-Methyl-1,2-Ethanediyl)-BIS-(2,6-Piperazinedione) | CYATHUS EXQUIRERE PHARMAFORSCHUNGS GMBH (AT) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152447-A1 | Novel Method for Producing 4,4-(1-Methyl-1,2-Ethanediyl)-BIS-(2,6-Piperazinedione) | CPS1, ABAT, ALDH7A1 | MGAM 2055/4885GAA 1868/4885SI 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.